BioSpace News Archive

Inmagene Biopharmaceuticals (“Inmagene”), a clinical stage biotechnology company developing innovative and differentiated therapies for immunological and inflammatory diseases, announced that the first patient has been dosed in a global multicenter Phase 2a study of IMG-007 in adult patients with AA.

Actinogen Medical Limited (ASX: ACW) CEO Dr Steven Gourlay will conduct a series of meetings at the BIO Investor Forum, San Francisco on October 17-18, 2023.

Shimadzu Medical Systems USA, a subsidiary of Shimadzu Corporation, is proud to announce the first U.S. installation of a Trinias SCORE Opera C12 (ceiling-mounted cutting edge angiography system) at Beaufort Memorial Hospital (Beaufort, SC).

VolitionRx Limited, a multi-national epigenetics company, has published a report summarising key themes from its recent Key Opinion Leader roundtable on sepsis management.

FOXO Technologies Inc. announced that the United States Patent & Trademark Office has provided an Issue Notification for a key patent utilizing a machine learning model trained to determine a biochemical state and/or medical condition using DNA epigenetic data to enable the commercialization of epigenetic biomarkers.

Scorpion Therapeutics, Inc announced preclinical data for STX-241, an orally bioavailable, highly selective, central nervous system -penetrant and potentially best-in-class fourth generation epidermal growth factor receptor tyrosine kinase inhibitor designed to inhibit C797S mutations with a co-occurring EGFR exon 19 deletion or exon 21 mutation in non-small cell lung cancer.

Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX) today announced that, in partnership with Moffitt Cancer Center, it has completed treatment of the first patient cohort in the ongoing clinical trial of Anixa’s novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer.

Trevi Therapeutics, Inc. (Nasdaq: TRVI) today announced the 52-week results from its phase 2b/3 PRISM open-label extension (OLE) study of Haduvio for the treatment of prurigo nodularis.

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved VELSIPITY™ (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator for adults with moderately to severely active ulcerative colitis (UC).

Alpine Immune Sciences, Inc. (NASDAQ: ALPN) announced the Company will present initial clinical data from RUBY-3, a phase 1b/2a study of povetacicept in autoimmune glomerulonephritis including IgA nephropathy, in a late breaking poster presentation at the American Society of Nephrology (ASN) Kidney Week, November 1-5, 2023 in Philadelphia, Pennsylvania.